References
- Barker WH. Excess pneumonia and influenza associated hospitalizations during influenza epidemics in the United States. Am. J. Public Health76, 761–765 (1986).
- Nichol KL, Lind A, Margolis KL et al. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med.333(14), 889–893 (1995).
- Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J. Infect. Dis.194(Suppl. 2), S111–S118 (2006).
- Guidance for Industry. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. May 2007.
- European Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products, 12 March 1997.
- Chaloupka I, Schuler A, Marschall M et al. Comparative analysis of six European influenza vaccines. Eur. J. Clin. Microbiol. Infect. Dis.15, 121–127 (1996).
- Agriflu, package insert. Novartis Vaccines and Diagnostics, Inc., Sienna, Italy.
- Frey S, Vesikari T, Szymczakiewicz-Multanowska A et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin. Infect. Dis.51(9), 997–1004 (2010).
- Agrippal, package insert. Novartis Vaccines and Diagnostics S.r.l., Siena, Italy.
- Lattanzi M, Rappuoli R. In: The Grand Challenge for the Future. Vaccines for Poverty-Related Diseases from Bench to Field. Kaufmann SHE, Lambert P (Eds). Birkhauser, Basel, Switzerland, 77–98 (2005).
- Plotkin SA, Plotkin SL. A short history of vaccination. In: Vaccines. Plotkin SA, Orenstein WA (Eds). Saunders, PA, USA (2008).
- Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep.57, 1–60 (2008).
- Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA292, 1333–1340 (2004).
- CDC. Estimates of deaths associated with seasonal influenza, United States, 1976–2007. MMWR59(33), 1057–1062 (2010).
- Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine25, 5086–5096 (2007).
- Couch RB, Keitel WA, Cate TR. Improvement of inactivated influenza virus vaccines. J. Infect. Dis.176(Suppl. 1), S38–S44 (1997).
- FluMist, package insert. MedImmune, LLC, MD, USA.
- Sy CL, Lee SS, Liu MT, Tsai HC, Chen YS. Rapid emergence of oseltamivir resistance. Emerg. Infect. Dis.16(4), 723–725 (2010).
- Prevention and Control of Influenza with Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morbidity Mortal. Wkly Rep.59(rr08), 1–62 (2010).
- Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–2010 influenza season: a multicentre, randomised controlled trial. Lancet375(9708), 49–55 (2010).
- Vajo Z, Wood J, Kosa L et al. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. J. Virol.84(3), 1237–1242 (2010).
- O’Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines10(4), 447–462 (2011).
- Barrett PN, Portsmouth D, Ehrlich HJ. Developing cell culture-derived pandemic vaccines. Curr. Opin. Mol. Ther.12(1), 21–30 (2010).
Websites
- WHO: Influenza Fact Sheet N 211. 2009 www.who.int/mediacentre/factsheets/fs211/en/index.html (Accessed 25 May 2011)
- WHO: Pandemic (H1N1) 2009 – update 112 www.who.int/csr/don/2010_08_06/en/index.html (Accessed 25 May 2011)
- Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old. NCT00464672 www.clinicaltrials.gov/ct2/show/NCT00464672?term=NCT00464672&rank=1 (Accessed 29 November 2010)
- Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old. NCT00617851 www.clinicaltrials.gov/ct2/show/NCT00617851?term=6.%09NCT00617851&rank=1 (Accessed 29 November 2010)
- Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects. NCT00630331 www.clinicaltrials.gov/ct2/show/NCT00630331?term=NCT00630331&rank=1 (Accessed 29 November 2010)